Maravai LifeSciences(NASDAQ) MRVI

Maravai LifeSciences Holdings, Inc. helps drug companies create new vaccines and gene therapies. It makes chemical building blocks and testing kits used to develop modern medicines. These products help researchers ensure that their therapies are safe.

Building Blocks for Medicine

• TriLink Segment: Produces messenger RNA (mRNA) and proprietary CleanCap technology for vaccines; represents 70% of revenue for the six months ended June 30, 2026.
• Cygnus Segment: Provides enzyme-linked immunosorbent assay (ELISA) kits to detect impurities in drug manufacturing; represents 30% of revenue for the six-month period ended June 30, 2026.
• Research Reagents: Offers chemical tools for labeling DNA and RNA in laboratory research and diagnostics.
• Contract Manufacturing: Provides services for scaling up nucleic acid production for clinical applications.

Growing the Business

• Acquired MyChem in January 2022 to expand its offering of specialized building blocks for nucleic acid production.
• Purchased Alphazyme in January 2023 to add specific enzymes used in molecular biology and molecular diagnostics.
• Executed the 2025 Corporate Realignment Plan to reduce operating expenses and improve efficiency.
• Entered into a new $150.0 million credit agreement in June 2026 to provide continued access to borrowing capacity.

Why Maravai Stands Out

Maravai maintains a technical workforce where 26% of its 415 employees hold advanced degrees to support research. North America accounted for 57.1% of total revenue for the six months ended June 30, 2026.

A Look at the Numbers

• Total revenue reached $117.3 million for the six months ended June 30, 2026, up 24.4% year over year.
• Adjusted EBITDA was $29.0 million for the six-month period ended June 30, 2026, compared to negative $21.0 million in 2025.
• Selling, general, and administrative expenses fell 21.9% to $61.2 million for the six months ended June 30, 2026.
• Cash and cash equivalents totaled $70.1 million as of June 30, 2026.

Bottom Line

Maravai has transitioned from pandemic-driven demand toward a broader focus on mRNA and biologics safety testing. Its focus on operational efficiency and specialized production supports its position in the drug development supply chain.